The delivery of these degraders into a mouse model of tauopathy (Tg2541), led to a reduction in Tau pathology, suggesting that this approach can be used to reduce Tau protein aggregates rapidly and durably at scale in the mammalian brain [119]. Here, MAPT is linked to tauopathy.